“We’ll be able to take care of ourselves” – A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs

References

• Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Doing harm reduction better: syringe exchange in the United States. Addiction. 2009;104(9):1441–1446.
   PubMed Web of Science ®Google Scholar
• Luoma JB, Twohig MP, Waltz T, et al. An investigation of stigma in individuals receiving treatment for substance abuse. Addict Behav. 2007;32(7):1331–1346.
   PubMed Web of Science ®Google Scholar
• Wakeman SE, Rich JD. Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction. J Gen Intern Med. 2017;32(1):17–19.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25(2):215–224.
   PubMed Web of Science ®Google Scholar
• Cunningham CO, Sohler NL, McCoy K, Kunins HV. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38(5):336–340.
   PubMed Web of Science ®Google Scholar
• Allen B, Harocopos A. Non-prescribed buprenorphine in New York City: motivations for use, practices of diversion, and experiences of stigma. J Subst Abuse Treat. 2016;70:81–86.
   PubMed Web of Science ®Google Scholar
• Saloner B, Karthikeyan S. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004–2013. JAMA. 2015;314(14):1515–1517.
   PubMed Web of Science ®Google Scholar
• Mund PA, Heller D, Meissner P, Matthews DW, Hill M, Cunningham CO. Delivering care out of the box: the evolution of an HIV harm reduction medical program. J Health Care Poor Underserved. 2008;19:944–951.
   PubMed Web of Science ®Google Scholar
• Einstein S. Harm and risk reduction: history, theories, issues, and implications. Subst Use Misuse. 2007;42(2–3):257–265.
   PubMed Web of Science ®Google Scholar
• New York State Department of Health, AIDS Institute. Comprehensive Harm Reduction Reverses the Trend in New HIV Infections. Albany, NY; 2014. https://www.health.ny.gov/diseases/aids/providers/reports/docs/sep_report.pdf
   Google Scholar
• Fox AD, Chamberlain A, Frost T, Cunningham CO. Harm reduction agencies as a potential site for buprenorphine treatment. Subst Abus. 2015;36(2):155–160.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
   PubMed Web of Science ®Google Scholar
• Woody GE, Bruce D, Korthuis PT, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr. 2014;66(3):288–293.
   PubMed Web of Science ®Google Scholar
• Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369–1376.
   PubMed Web of Science ®Google Scholar
• Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban.community health center: what to expect. Fam Med. 2008;40:500–506.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004. DHHS Publication No. (SMA) 04-3939.
   Google Scholar
• Murphy SM, Fishman PA, McPherson S, Dyck DG, Roll JR. Determinants of buprenorphine treatment for opioid dependence. J Subst Abuse Treat. 2014;46(3):315–319.
   PubMed Web of Science ®Google Scholar
• Baxter JD, Clark RE, Samnaliev M, Leung GY, Hashemi L. Factors associated with Medicaid patients' access to buprenorphine treatment. J Subst Abuse Treat. 2011;41(1):88–96.
   PubMed Web of Science ®Google Scholar
• Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628–635.
   PubMed Web of Science ®Google Scholar
• Rhodes T. The “risk environment”: a framework for understanding and reducing drug-related harm. Int J Drug Policy. 2002;13(2):85–94.
   Google Scholar
• Heller D, McCoy K, Cunningham C. An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models. Public Health Rep. 2004;119(1):32–39.
   PubMed Web of Science ®Google Scholar
• Namba MD, Tomek SE, Olive MF, Beckmann JS, Gipson CD. The winding road to relapse: forging a new understanding of cue-induced reinstatement models and their associated neural mechanisms. Front Behav Neurosci. 2018;12:17.
   PubMed Web of Science ®Google Scholar
• Bossert JM, Marchant NJ, Calu DJ, Shaham Y. The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research. Psychopharmacology (Berl). 2013;229(3):453–476.
   PubMed Web of Science ®Google Scholar
• Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77–101.
   Google Scholar
• Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104–110.
   PubMed Web of Science ®Google Scholar
• van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1–2):23–35.
   PubMed Web of Science ®Google Scholar
• Kennedy-Hendricks A, Busch SH, McGinty EE, et al. Primary care physicians' perspectives on the prescription opioid epidemic. Drug Alcohol Depend. 2016;165:61–70.
   PubMed Web of Science ®Google Scholar
• Earnshaw V, Smith L, Copenhaver M. Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma. Int J Ment Health Addict. 2013;11(1):110–122.
   PubMed Web of Science ®Google Scholar
• Maradiaga JA, Nahvi S, Cunningham CO, Sanchez J, Fox AD. “I kicked the hard way. I got incarcerated.” withdrawal from methadone during incarceration and subsequent aversion to medication assisted treatments. J Subst Abuse Treat. 2016;62:49–54.
   PubMed Web of Science ®Google Scholar
• Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of drug users: the keys to the “narc” cabinet. J Gen Intern Med. 2002;17(5):327–333.
   PubMed Web of Science ®Google Scholar
• Bachhuber MA, Thompson C, Prybylowski A, Benitez JM, Mazzella SM, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abus. 2018;39(2):167–172.
   PubMed Web of Science ®Google Scholar
• Tringale R, Subica AM, Danielian A, Kaplan C. The stepped treatment engagement protocol for homeless, needle exchange heroin-dependent patients. J Addict Med. 2015;9(2):163–164.
   PubMed Web of Science ®Google Scholar
• Wood E, Tyndall MW, Zhang R, Montaner JS, Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction. 2007;102(6):916–919.
   PubMed Web of Science ®Google Scholar
• Kenney SR, Anderson BJ, Bailey GL, Stein MD. The relationship between diversion-related attitudes and sharing and selling buprenorphine. J Subst Abuse Treat. 2017;78:43–47.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33–40.
   PubMed Web of Science ®Google Scholar